UK – NICE nod for Almirall’s Ilumetri, UCB’s Cimzia

The National Institute for Health and Care Excellence (NICE) has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque psoriasis in final draft guidelines.

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price submitted by the company means that it can now be offered as an alternative for patients who are unable to take systemic non-biological treatments.

The drug was approved in September 2018 on the back of data from the Resurface I and ii trials, in which an average of 63% of patients achieved 75% of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) by week 12 and an average of 78% at week 28 after three doses, before being deemed not cost-effective.

Clinical trial results show that the treatment improves severe psoriasis more than placebo or etanercept, a drug which is already recommended by NICE.

Meanwhile, UCB’s Cimzia was also recommended in final draft guidance for adults with severe plaque psoriasis that has not responded to other systemic treatments such as phototherapy, methotrexate and ciclosporin, or if these treatments are not suitable…